Amedisys Inc (NASDAQ:AMED) had its target price increased by Robert W. Baird from $50.00 to $60.00 in a research note released on Friday morning. They currently have a neutral rating on the health services provider’s stock.

A number of other equities analysts have also recently issued reports on the company. Mizuho cut Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. BidaskClub cut Amedisys from a hold rating to a sell rating in a report on Saturday, August 5th. Bank of America Corporation began coverage on Amedisys in a report on Monday, August 21st. They issued a neutral rating and a $55.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a research note on Friday, September 15th. Finally, SunTrust Banks, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a research note on Monday, October 9th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $61.00.

Amedisys (AMED) traded down $0.14 during mid-day trading on Friday, hitting $56.25. The stock had a trading volume of 310,900 shares, compared to its average volume of 322,348. Amedisys has a 52 week low of $38.00 and a 52 week high of $65.91. The company has a market cap of $1,908.94, a price-to-earnings ratio of 26.91, a P/E/G ratio of 1.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.02. The firm had revenue of $380.20 million for the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.36 EPS. research analysts expect that Amedisys will post 2.22 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Robert W. Baird Boosts Amedisys Inc (AMED) Price Target to $60.00” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/13/robert-w-baird-boosts-amedisys-inc-amed-price-target-to-60-00.html.

A number of large investors have recently made changes to their positions in AMED. American Century Companies Inc. increased its stake in Amedisys by 41.4% in the third quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock valued at $93,547,000 after acquiring an additional 489,220 shares during the last quarter. Wells Fargo & Company MN increased its stake in Amedisys by 29.7% in the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after acquiring an additional 339,825 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Amedisys by 662.7% in the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock valued at $17,387,000 after acquiring an additional 240,513 shares during the last quarter. Balyasny Asset Management LLC bought a new position in Amedisys in the second quarter valued at approximately $7,736,000. Finally, TimesSquare Capital Management LLC increased its stake in Amedisys by 15.7% in the second quarter. TimesSquare Capital Management LLC now owns 731,670 shares of the health services provider’s stock valued at $45,956,000 after acquiring an additional 99,380 shares during the last quarter. 94.62% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.